Baird Medical Investment Holdings vs Vivos Therapeutics
Baird Medical Investment Holdings is the larger business, with $22.5m of revenue in fiscal 2025 against $17.4m for Vivos Therapeutics (1.3 times as much). Vivos Therapeutics grew faster (16.0% against -39.2%). Baird Medical Investment Holdings kept more of each dollar of sales as profit: a net margin of -121.0% against -121.4%.
| Latest fiscal year | Baird Medical Investment HoldingsBDMD, 2025 | Vivos TherapeuticsVVOS, 2025 |
|---|---|---|
| Revenue | $22.5m | $17.4m |
| Revenue growth | -39.2% | 16.0% |
| Net income | −$27.3m | −$21.2m |
| Operating margin | -113.7% | -114.1% |
| Net margin | -121.0% | -121.4% |
| Return on equity | -76.8% | — |
| Free cash flow | −$1.4m | −$17.6m |
| Cash | $178,321 | $2.0m |
| Total debt | $8.7m | $19.3m |
| Debt to equity | 27.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 268 |
| Market value | $4.2m | $1.6m |
| Price vs our value range | — | — |
| Moat score | — | 30 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 0 sales |